Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter h. pylori treatment may work just as well as longer one

NCT ID NCT07333001

Disease control Sponsor: Yueyue Li Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at 508 adults with H. pylori infection to see if a 7-day triple therapy (vonoprazan, amoxicillin, tetracycline) works as well as a 14-day dual therapy (vonoprazan, amoxicillin). The goal was to compare how often the infection is cleared and how many side effects occur. The study used past medical records from a hospital in China.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vonoprazan, amoxicillin, and tetracycline
What this could lead to
If successful, a shorter 7-day treatment could be as effective as the standard 14-day regimen, making it more convenient for patients.
What could go wrong
This is a retrospective study, not a randomized trial, so results may be less reliable. The shorter regimen may not work as well in people with antibiotic resistance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

508 people

The number who actually took part.

Started

Nov 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* patients aged 18-70 years; * patients with H. pylori infection confirmed by 13C/14C-urea breath test or rapid urease test; * patients with no history of H. pylori eradication therapy

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients aged 18-70 years; * patients with H. pylori infection confirmed by 13C/14C-urea breath test or rapid urease test; * patients with no history of H. pylori eradication therapy Exclusion Criteria: * patients with severe underlying diseases, such as hepatic insufficiency, renal insufficiency, immunosuppression, malignant tumors, and coronary heart disease; * patients with active gastrointestinal bleeding; * patients with a history of upper gastrointestinal surgery; * patients allergic to treatment drugs; * patients with medication history of bismuth, antibiotics within 4 weeks, or proton pump inhibitors within 2 weeks; * patients who were pregnant or lactating or unwilling to take contraceptive measures during the trial; * patients with other behaviors that may increase the risk of disease, such as alcohol and drug abuse; * incomplete data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Helicobacter pylori infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Helicobacter pylori infections

Contacts and locations

Locations

  • Qilu Hospital of Shandong University

    Jinan, Shandong, 250012, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.